


## Drug Status Report

**Drug:** 5 $\alpha$ -Androstano-[2,3-*c*]-furazan-17 $\beta$ -tetrahydropyranol ether

**Drug Name Status:** 5 $\alpha$ -Androstano-[2,3-*c*]-furazan-17 $\beta$ -tetrahydropyranol ether is the chemical name

**Other Names:** Furazadrol; Furazadrol-THP ether; 5 $\alpha$ -Etioallocholan-[2,3-*c*]-furazan-17 $\beta$ -tetrahydropyranol ether

**Chemical structure:**



**Molecular Formula:** C<sub>24</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub>

**Pharmacological class / Application:** steroid

**International status:**

US: The substance is not listed on the schedules to the CSA and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 5 $\alpha$ -Androstano-[2,3-*c*]-furazan-17 $\beta$ -tetrahydropyranol ether<sup>1</sup> is not listed on the Schedules to the CDSA. The parent steroid, 17 $\beta$ -hydroxy-5 $\alpha$ -Androstano-[2,3-*c*]-furazan, has been shown in *in vivo* studies to display anabolic activity<sup>2</sup> and therefore both 17 $\beta$ -hydroxy-5 $\alpha$ -Androstano-[2,3-*c*]-furazan and its 17 $\beta$ -tetrahydropyranol ether derivative are considered to be included under the heading “Anabolic steroids and their derivatives” of Item 23 of Schedule IV to the CDSA

---

<sup>1</sup>Parr, MK. *et al.* (2009) Identification of steroid isoxazole isomers marketed as designer supplement, *Steroids*, **74**:322-328.

<sup>2</sup>Kasahara, A. *et al.* (1965) Investigations on Steroids. V. Pharmacological studies (1) Anabolic and androgenic activities of 17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androstano[2,3-*c*]furazan (Androfurazanol), a new active anabolic steroid, *Chem. Pharm. Bull.* **13**:1460-1469.

Recommendation: 5 $\alpha$ -Androstano-[2,3-*c*]-fuzazan-17 $\beta$ -tetrahydropyranol ether is included under Item 23 of Schedule IV to the CDSA and is a controlled substance.

16 March 2010.